BORA PHARMACEUTICALS LTD (6472) - Total Assets
Based on the latest financial reports, BORA PHARMACEUTICALS LTD (6472) holds total assets worth NT$45.33 Billion TWD (≈ $1.43 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BORA PHARMACEUTICALS LTD - Total Assets Trend (2019–2025)
This chart illustrates how BORA PHARMACEUTICALS LTD's total assets have evolved over time, based on quarterly financial data. Also see 6472 market cap overview for the company's overall valuation and market capitalisation.
BORA PHARMACEUTICALS LTD - Asset Composition Analysis
Current Asset Composition (September 2025)
BORA PHARMACEUTICALS LTD's total assets of NT$45.33 Billion consist of 43.3% current assets and 56.8% non-current assets. Review BORA PHARMACEUTICALS LTD balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 11.4% |
| Accounts Receivable | NT$9.60 Billion | 21.5% |
| Inventory | NT$3.41 Billion | 7.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$3.58 Billion | 8.0% |
| Goodwill | NT$2.66 Billion | 6.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how BORA PHARMACEUTICALS LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See BORA PHARMACEUTICALS LTD (6472) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BORA PHARMACEUTICALS LTD's current assets represent 43.3% of total assets in 2025, an increase from 36.8% in 2019.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2025, down from 13.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 21.5% of total assets.
BORA PHARMACEUTICALS LTD Competitors by Total Assets
Key competitors of BORA PHARMACEUTICALS LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥22.22 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC
|
Turkey | TL70.69 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥10.50 Billion |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
China | CN¥2.33 Billion |
BORA PHARMACEUTICALS LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 1.42 | 1.16 |
| Quick Ratio | 1.12 | 1.15 | 0.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$5.47 Billion | NT$6.49 Billion | NT$1.74 Billion |
BORA PHARMACEUTICALS LTD - Advanced Valuation Insights
This section examines the relationship between BORA PHARMACEUTICALS LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.65 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -1.9% |
| Total Assets | NT$44.71 Billion |
| Market Capitalization | $1.65 Billion USD |
Valuation Analysis
Below Book Valuation: The market values BORA PHARMACEUTICALS LTD's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: BORA PHARMACEUTICALS LTD's assets decreased by 1.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for BORA PHARMACEUTICALS LTD (2019–2025)
The table below shows the annual total assets of BORA PHARMACEUTICALS LTD from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | NT$44.71 Billion ≈ $1.41 Billion |
-1.94% |
| 2024-09-30 | NT$45.60 Billion ≈ $1.44 Billion |
+82.02% |
| 2023-09-30 | NT$25.05 Billion ≈ $789.28 Million |
+10.06% |
| 2022-09-30 | NT$22.76 Billion ≈ $717.10 Million |
+208.74% |
| 2021-09-30 | NT$7.37 Billion ≈ $232.27 Million |
+5.26% |
| 2020-09-30 | NT$7.00 Billion ≈ $220.67 Million |
+107.06% |
| 2019-09-30 | NT$3.38 Billion ≈ $106.57 Million |
-- |
About BORA PHARMACEUTICALS LTD
Bora Pharmaceuticals Co., LTD. engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally. The company operates through Sales, CDMO, and Other segments. It manufactures and sells generic, brand, and over the counter (OTC) drugs. The company also offers contract development and manufacturing services and technical services fo… Read more